ERBB2 and neoplasm: The in vitro and in vivo treatment of different concentrations of MRK-003, either alone or in combination with lapatinib, trastuzumab, and docetaxel, resulted in Notch-1 inhibition, prevented mammosphere formation, inhibited the proliferation of bulk HER2+ HCC1954 cells, and prevented tumor relapse in xenograft models [86], and suppressed Notch signaling activation and decreased the number of CSCs, while a combination of MRK-003 and docetaxel enhanced this activity [87].